8-K - AYTU - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2023

AYTU BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)


Delaware	****	001-38247	****	47-0883144
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

373 Inverness Parkway , Suite 206

Englewood , CO **** 80112

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: ( 720 ) 437-6580

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	****	Trading Symbol(s)	****	Name of each exchange on which registered
Common Stock, par value $0.0001 per share		AYTU		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

****

On August 11, 2023 the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Aytu BioPharma, Inc. (“Aytu” or the “Company”) approved the following bonus for the Named Executive Officers (“NEOs”):

Name	****	Title	****	Bonus<br><br>Amount	****	% of Target	****
Joshua R. Disbrow		Chief Executive Officer		$118,000		33%
Mark K. Oki		Chief Financial Officer & Secretary		$ 83,000		50%

The bonuses earned by Mr. Disbrow and Mr. Oki will be paid in January 2024. If Mr. Disbrow or Mr. Oki’s employment terminates prior to January 2024, the approved bonus will be paid in full.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Aytu BioPharma, Inc.
Date: August 15, 2023	By:	/s/ Mark K. Oki
		Mark K. Oki
		Chief Financial Officer